Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Myriad Genetics, Inc. MYGN

Healthcare — Diagnostics & Research
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.72
Total sells
0.07
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — 1 1 — 1 — — — —
Sell — — — — — — — — 1 — — —
Insider Ownership
6.17%

Capital & Financial Ratios

Market Cap
395.99
Revenue
806.60
Net Income
(112.60)
Free Cash Flow
(14.20)
Net Debt
5.50
Current Ratio
2.21
Debt/Equity
0.40
P/E ratio
0.00
P/S ratio
0.46
P/B ratio
1.21
Past 5Y EPS Growth
—
This Y EPS Growth
(1,324.42%)
Next Y EPS Growth
21.98%
Next 5Y EPS Growth
16.55%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 140.90 102.40 149.60 115.20
Receivables 114.30 121.20 115.30 109.50
Inventory 22.00 27.50 30.60 30.60
Other — — — —
313.60 298.00 332.60 289.00
2023 2024 2025 Q'26
Payables 25.80 32.30 30.00 30.40
ST’ Debt — — — —
Other — — — —
155.90 164.10 133.80 130.70
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 200.40 190.70 — —
—
’25 195.90 213.10 205.70 209.80
824.50
’24 202.20 211.50 213.30 210.60
837.60
’23 181.20 183.50 191.90 196.60
753.20
’22 — — 156.40 177.80
678.40
’22 164.90 179.30 — —
678.40
’21 — — 167.30 160.80
690.60
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (15.70) (8.30) — —
—
’25 (16.30) (13.60) 21.10 10.60
1.80
’24 (18.60) 2.60 0.70 6.60
(8.70)
’23 (33.20) (0.90) (22.10) (54.70)
(110.90)
’22 — — (2.80) (7.30)
(106.30)
’22 (46.50) (49.70) — —
(107.00)
’21 — — (39.30) (9.50)
18.60
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (22.20) (11.50) — —
—
’25 (24.60) (20.50) 14.90 4.60
(25.60)
’24 (27.20) (6.30) 3.20 (8.10)
(38.40)
’23 (56.70) (19.70) (39.60) (68.20)
(184.20)
’22 — — (20.50) (21.90)
(151.60)
’22 (52.80) (56.40) — —
(107.00)
’21 — — (42.30) (12.90)
0.60
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.36) (0.46) — —
—
’25 0.00 (3.57) (0.29) (0.08)
(3.95)
’24 (0.29) (0.41) (0.24) (0.47)
(1.41)
’23 (0.67) (1.42) (0.75) (0.36)
(3.18)
’22 — — (0.43) (0.52)
(1.39)
’22 (0.26) (0.18) — —
(1.39)
’21 — — 0.30 (0.10)
(0.35)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

3.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 13.92 13.82 12.87 3.76 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.45 24.21 29.30 15.47 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,600 2,700 2,700 2,700 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.28 0.31 0.31 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 678.40 753.20 837.60 824.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64.17% 68.64% 69.89% 69.93% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (140.60) (262.20) (123.50) (395.10) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.73%) (34.81%) (14.74%) (47.92%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (112.00) (263.30) (127.30) (365.90) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64.40 61.90 117.80 373.10 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.42 9.10 9.25 8.90 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.39) (3.18) (1.41) (3.95) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.33) (1.34) (0.10) 0.02 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 (0.89) (0.33) (0.30) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.33) (2.22) (0.42) (0.28) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.99 9.46 7.74 3.97 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 80.60 82.80 90.60 92.60 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.17 2.09 1.48 0.69 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.54 2.01 1.77 1.55 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.02 1.98 1.43 0.73 ‡‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.25) (8.08) (31.18) (23.41) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (107.00) (110.90) (8.70) 1.80 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (45.30) (73.30) (29.70) (27.40) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (107.00) (184.20) (38.40) (25.60) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 138.00 157.70 133.90 198.80 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 145.00 38.50 39.60 119.90 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.00 (102.40) (62.80) (29.70) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 886.00 783.20 701.10 368.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.49%) (22.45%) (11.71%) (42.20%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00% (23.63%) (12.09%) (71.53%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (12.08%) (31.55%) (17.15%) (68.45%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Myriad Genetics (MYGN), a trailblazer in hereditary cancer testing since its BRCA1/2 breakthroughs, has endured a decade of headwinds including reimbursement squeezes, COVID disruptions, and fierce competition, yet demonstrated revenue resilience—from $741 million in 2016 to a projected $921 million by 2027 at a modest 2-6% CAGR. While testing volumes and the 2023 SneakPeek acquisition fueled a post-pandemic rebound to $838 million in 2024, gross margins stabilized at 70% after erosion, but profitability remains elusive with cumulative net losses exceeding $600 million since 2020 and volatile EPS swinging from profits to -$1.41. Shares, mirroring these fundamentals, plunged from $40+ highs to sub-$15 troughs, now languishing near multi-year lows amid undervalued sales multiples (PS 1.5x, EV/Sales 1.4x).

Cash flow hints at stabilization with a net cash position and moderating capex, supporting a balance sheet floor despite book value erosion and share dilution. Analyst forecasts eye revenue acceleration and FCF positivity by 2025, with consensus price targets implying 56% upside (high end 300%), though wide dispersion underscores profitability risks and breakeven fragility into 2027.

Echoing historical diagnostics cycles like post-patent loss rebounds, MYGN’s setup tempts patient investors if margin leverage materializes via prenatal expansion and oncology tailwinds—but payer pushback and execution missteps loom large in this volatile sector.

Read full commentary →

Myriad Genetics, Inc. (MYGN) Latest News

News by impact score

Fine-tune

18 Sep

3 , 3:14 AM
Myriad Genetics stock fair value fell after analysts cut ratings and the company reset guidance. Analyst downgrades combined with guidance reset directly reduce valuation targets and near-term investor expectations.

1 Sep

4 , 12:37 PM
Myriad Genetics stock received a rare double-downgrade after analysts highlighted its worsening profitability issues. Double-downgrade directly pressures investor sentiment and stock trajectory due to emphasized profitability deterioration.

3 Aug

3 , 2:07 AM
Myriad Genetics missed Q2 earnings estimates and cut full-year guidance, leaving shares trading 54% below estimated fair value. Q2 miss combined with guidance cut directly pressures near-term financial results and sentiment.

2 Aug

4 , 1:09 AM
Myriad Genetics cut its 2026 revenue outlook due to weakness in prenatal tests, triggering a 49.0% stock decline. Revenue forecast reduction and 49% share price drop reflect major headwinds in core prenatal testing that will weigh on future financial results and valuation.

31 Jul

3 transcript www.marketbeat.com, 9:02 PM
Myriad Genetics reported Q2 financial results and discussed operational updates along with future outlook during its earnings call. Q2 earnings and guidance directly inform near-term financial expectations and investor sentiment for the company.

3 transcript , 1:04 AM
Myriad Genetics reported Q2 2026 revenue down 11 percent amid ongoing payer reimbursement pressures, with management highlighting cost controls and pipeline updates during the earnings call. Eleven percent revenue decline tied to payer issues points to sustained pressure on near-term financial results and investor sentiment.

30 Jul

4 , 4:45 PM
Myriad Genetics reported Q2 CY2026 sales below analyst estimates, triggering a 28.6% stock drop. Earnings miss and 28.6% stock plunge indicate material negative pressure on near-term financial outlook and investor confidence.

3 , 4:05 PM
Myriad Genetics reported second quarter 2026 financial results and is deploying new initiatives to drive increased efficiency, productivity and scalability. Quarterly results release plus efficiency initiatives indicate moderate effects on operations and near-term performance.

27 Jul

3 www.businessinsider.com, 5:08 PM
Myriad Genetics rebuilt its AI platform after costs ballooned, enabling document processing in seconds. AI platform rebuild improves internal document processing efficiency with moderate long-term operational benefits.

21 Jul

4 , 9:05 AM
Myriad Genetics launches FirstGene® Multiple Prenatal Screen product. New prenatal screen product launch strengthens core genetic testing revenue and competitive position.

2 Jul

3 , 9:05 AM
Myriad’s Prolaris biopsy test exhibits strong prognostic performance for localized prostate cancer per new large-scale meta-analysis. Meta-analysis affirming Prolaris efficacy supports increased clinical use and revenue potential for Myriad Genetics.

24 Jun

4 StockStory, 3:12 PM
Myriad Genetics (MYGN) stock surges sharply higher today on positive developments affecting the company. Sharp stock advance signals major near-term catalyst likely to influence investor views and company trajectory.

23 Jun

3 GlobeNewswire, 9:05 AM
Myriad Genetics expands Precise MRD™ availability to colorectal, renal and breast cancers supported by new publication. Product expansion to new cancer types strengthens Myriad's MRD offerings and revenue potential.

3 Jun

3 , 4:20 PM
Dr. Crystal Nelson discusses on YourUpdateTV how genetic testing is transforming mental health medication selection and outcomes, spotlighting Myriad Genetics' pharmacogenomic solutions. TV segment increases visibility for Myriad's mental health genetic testing without announcing major business or financial shifts.

28 May

4 Zacks, 9:24 AM
Myriad Genetics prepares launch of Prolaris plus AI test expected to increase company stock value. Upcoming AI-enhanced Prolaris test launch signals major product innovation likely to alter Myriad Genetics trajectory and investor sentiment.

27 May

4 Zacks, 8:48 AM
Myriad Genetics outlines cancer care strategy to drive growth through 2026. Myriad Genetics cancer care strategy details major growth initiatives through 2026.

26 May

4 GlobeNewswire, 4:05 PM
Myriad Genetics launches Prolaris + AI, the first prostate cancer test combining genomics and digital pathology AI. First-of-kind AI-genomics prostate cancer test launch strengthens competitive position in precision oncology.

14 May

3 StockStory, 11:00 PM
Myriad Genetics Q1 earnings call highlights top 5 analyst questions on financial performance, product pipeline, and strategic outlook. Q1 earnings call top analyst questions reveal insights into financials and strategy with moderate potential to sway investor sentiment.

6 May

4 app.moby.co, 8:30 AM
Myriad Genetics, Inc. (MYGN) Q1 2026 earnings call summary details the company's quarterly financial performance, revenue growth, strategic initiatives, and future outlook. Q1 2026 earnings summary provides key financial metrics, guidance, and strategic updates that significantly influence MYGN's trajectory and investor sentiment.

5 May

4 StockStory, 4:16 PM
Myriad Genetics (NASDAQ:MYGN) missed Q1 CY2026 sales expectations, resulting in a 16.2% drop in its stock price. Earnings miss and 16.2% stock plunge signal significant short-term pressure on financial performance and investor confidence.

3 www.marketbeat.com, 9:35 PM
Myriad Genetics reported Q1 earnings call highlights, including revenue growth, product performance updates on hereditary cancer tests like myRisk, operational improvements, and forward guidance amid competitive pressures in molecular diagnostics. Q1 earnings highlights moderately impact financial performance and market sentiment through revenue figures and guidance.

3 , 8:30 PM
Myriad Genetics (MYGN) reported a Q1 net loss of $23.5 million, or $0.30 per share, compared to a profit last year, with revenue of $198 million missing analyst estimates by 2.5%. Q1 loss and revenue miss highlight financial weakness, likely causing short-term stock pressure and investor caution.

3 GlobeNewswire, 4:05 PM
Myriad Genetics reported first-quarter 2026 financial results and reiterated its full-year 2026 guidance, highlighting ongoing progress in the Cancer Care Continuum business. Q1 2026 results and reaffirmed annual guidance reflect moderate positive impact on financial performance and investor sentiment.

4 May

3 StockStory, 8:20 AM
Myriad Genetics (MYGN) reports earnings tomorrow with analysts forecasting revenue of $191.5 million, up 7.6% year-over-year, EPS of $0.37, and highlighting oncology and women's health segment growth amid Payerne acquisition integration. Earnings previews shape investor expectations and can moderately sway short-term stock performance ahead of results.

30 Apr

3 GlobeNewswire, 9:05 AM
Myriad Genetics' national survey reveals 88% of patients with depression and/or anxiety would feel more confident with a personalized mental health care plan. Survey shows strong patient demand for personalized mental health plans, supporting Myriad Genetics' genetic testing in mental health.

28 Apr

3 Zacks, 10:00 AM
Analysts forecast Myriad Genetics (MYGN) to report declining earnings, urging investors to monitor key metrics amid expected financial downturn. Expected earnings decline moderately affects MYGN's financial performance and investor sentiment.

16 Apr

4 Zacks, 12:52 PM
Tempus AI expands strategic partnership with Myriad Genetics amid oncology sector boom. Expansion of strategic oncology partnership enhances Myriad Genetics' competitive positioning and growth prospects.

14 Apr

4 GlobeNewswire, 9:15 AM
Myriad Genetics expands access to its MyChoice genetic test for prostate cancer patients in Japan, enabling broader use of the HRD biomarker test in oncology care. International expansion of MyChoice test to prostate cancer in Japan enhances revenue potential and market positioning in precision oncology.

9 Apr

3 GlobeNewswire, 9:15 AM
Myriad Genetics presented new data at the Society of Gynecologic Oncology (SGO) Annual Meeting, underscoring commitment to the cancer care continuum through advancements in genetic testing and precision medicine. New data presentations at SGO bolster Myriad's cancer diagnostics profile with moderate potential to influence financials and market sentiment.

6 Apr

4 StockStory, 3:51 AM
Myriad Genetics (NASDAQ:MYGN) Q4 earnings highlighted and compared to other therapeutics stocks. Q4 earnings highlights versus therapeutics peers signal key financial performance shifts influencing MYGN's trajectory and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us